RubrYc Therapeutics, Inc., is a biotechnology company applying proprietary machine-learning solutions to discover epitope-selective biologics. Inspired by recent advances in molecular library synthesis, massively parallel screening and computing, RubrYc is forging a new path for information-driven discovery of epitope-targeted drug candidates. RubrYc deploys our artificial intelligence and molecular engineering capabilities in the ELS System:
1. Epitope: discover and develop Meso-scale Engineered Molecules (MEMs), our proprietary antigens that embody prescribed epitopes
2. Library: design, produce, and select focused immune repertoires unique to each campaign (in vivo & in vitro)
3. Screen: Phage to Mammalian display for high-affinity, high-expression, high-stability clones
RubrYc is a flexible and reliable discovery partner, accommodating multiple partnership models covering the span of biologics discovery activities. We will raise Series B to advance pipeline and go to clinic.
1. Epitope: discover and develop Meso-scale Engineered Molecules (MEMs), our proprietary antigens that embody prescribed epitopes
2. Library: design, produce, and select focused immune repertoires unique to each campaign (in vivo & in vitro)
3. Screen: Phage to Mammalian display for high-affinity, high-expression, high-stability clones
RubrYc is a flexible and reliable discovery partner, accommodating multiple partnership models covering the span of biologics discovery activities. We will raise Series B to advance pipeline and go to clinic.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
RTX-003 out-licensed to iBio, Inc.
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
